e3d71c3f-4e56-45fa-be88-2cf444b70a5c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.400
- PANCREAS_BETA_CELLS+0.300
- WNT_BETA_CATENIN_SIGNALING+0.300
- HEDGEHOG_SIGNALING+0.200
- KRAS_SIGNALING_DN+0.200
- MYOGENESIS+0.200
- BILE_ACID_METABOLISM+0.100
- COAGULATION+0.100
- UV_RESPONSE_DN+0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.000
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.600
- E2F_TARGETS-0.600
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- OXIDATIVE_PHOSPHORYLATION-0.600
- G2M_CHECKPOINT-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INFLAMMATORY_RESPONSE-0.500
- MTORC1_SIGNALING-0.500
- MYC_TARGETS_V1-0.500
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-A49A-01A-11R-A24H-07 | — | — | 0.910 |
| 2 | TCGA-78-7161-01A-11R-2039-07 | — | cohortA3 | 0.908 |
| 3 | d2995480-5ae0-42e1-9a21-25e1435201ee | — | — | 0.906 |
| 4 | TCGA-ZF-A9RC-01A-11R-A38B-07 | — | — | 0.901 |
| 5 | TCGA-WA-A7H4-01A-21R-A34R-07 | — | — | 0.901 |
| 6 | TCGA-CN-4737-01A-01R-1436-07 | — | — | 0.889 |
| 7 | fe036511-fe82-467c-9c6e-59bfb8b0a329 | — | — | 0.884 |
| 8 | TCGA-55-8615-01A-11R-2403-07 | — | cohortA3 | 0.883 |
| 9 | TCGA-UF-A7JA-01A-12R-A34R-07 | — | — | 0.883 |
| 10 | C3N-03921 | — | cohortA1 | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |